The aberrant activation of PI3K/AKT/mTOR occursin more than 50% of AML cases, as many as 88% of ALL cases, and in both CML and CLL[58]. This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.